Phosphotyrosine Binding Domain-Dependent Upregulation of the Platelet-Derived Growth Factor Receptor α Signaling Cascade by Transforming Mutants of Cbl: Implications for Cbl’s Function and Oncogenicity
Authors:
Open Access
- 1 August 1997
- journal article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 17 (8) , 4597-4610
Abstract
Recent studies have demonstrated that Cbl, the 120-kDa protein product of the c-cbl proto-oncogene, serves as a substrate of a number of receptor-coupled tyrosine kinases and forms complexes with SH3 and SH2 domain-containing proteins, pointing to its role in signal transduction. Based on genetic evidence that the Caenorhabditis elegans Cbl homolog, SLI-1, functions as a negative regulator of the LET-23 receptor tyrosine kinase and our demonstration that Cbl's evolutionarily conserved N-terminal transforming region (Cbl-N; residues 1 to 357) harbors a phosphotyrosine binding (PTB) domain that binds to activated ZAP-70 tyrosine kinase, we examined the possibility that oncogenic Cbl mutants may activate mitogenic signaling by deregulating cellular tyrosine kinase machinery. Here, we show that expression of Cbl-N and two other transforming Cbl mutants (CblY368 delta and Cbl366-382 delta or Cb170Z), but not wild-type Cbl, in NIH 3T3 fibroblasts leads to enhancement of endogenous tyrosine kinase signaling. We identified platelet-derived growth factor receptor alpha (PDGFR alpha) as one target of mutant Cbl-induced deregulation. In mutant Cbl transfectants, PDGFR alpha was hyperphosphorylated and constitutively complexed with a number of SH2 domain-containing proteins. PDGFR alpha hyperphosphorylation and enhanced proliferation of mutant Cbl-transfected NIH 3T3 cells were drastically reduced upon serum starvation, and PDGF-AA substituted for the maintenance of these traits. PDGF-AA stimulation of serum-starved Cbl transfectants induced the in vivo association of transfected Cbl proteins with PDGFR alpha. In vitro, Cbl-N directly bound to PDGFR alpha derived from PDGF-AA-stimulated cells but not to that from unstimulated cells, and this binding was abrogated by a point mutation (G306E) corresponding to a loss-of-function mutation in SLI-1. The Cbl-N/G306E mutant protein, which failed to induce enhanced growth and transformation of NIH 3T3 cells, also failed to induce hyperphosphorylation of PDGFR alpha. Altogether, these findings identify a novel mechanism of Cbl's physiological function and oncogenesis, involving its PTB domain-dependent direct interaction with cellular tyrosine kinases.Keywords
This publication has 49 references indexed in Scilit:
- A Novel Phosphotyrosine-binding Domain in the N-terminal Transforming Region of Cbl Interacts Directly and Selectively with ZAP-70 in T CellsJournal of Biological Chemistry, 1996
- Tyrosine Phosphorylation of Cbl upon Epidermal Growth Factor (EGF) Stimulation and Its Association with EGF Receptor and Downstream Signaling ProteinsJournal of Biological Chemistry, 1996
- Does this have a familiar RING?Trends in Biochemical Sciences, 1996
- Interactions of Cbl with Two Adaptor Proteins, Grb2 and Crk, upon T Cell ActivationJournal of Biological Chemistry, 1996
- Tyrosine Phosphorylation of the c-cbl Proto-oncogene Product Mediated by Cell Surface Antigen CD38 in HL-60 CellsJournal of Biological Chemistry, 1996
- Association of Activated Phosphatidylinositol 3-Kinase with p120cbl in Antigen Receptor-ligated B CellsJournal of Biological Chemistry, 1995
- TPO/c-mpl Ligand Induces Tyrosine Phosphorylation of Multiple Cellular Proteins Including Proto-oncogene Products, Vav and c-Cbl, and Ras Signaling MoleculesBiochemical and Biophysical Research Communications, 1995
- Coupling of the Proto-oncogene Product c-Cbl to the Epidermal Growth Factor ReceptorJournal of Biological Chemistry, 1995
- T Cell Activation-dependent Association between the p85 Subunit of the Phosphatidylinositol 3-Kinase and Grb2/Phospholipase C-γ1-binding Phosphotyrosyl Protein pp36/38Journal of Biological Chemistry, 1995
- Oncogenes, Growth Factors, and Signal TransductionNew England Journal of Medicine, 1989